Clinical Trials Logo

Aplastic Anemia clinical trials

View clinical trials related to Aplastic Anemia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06430788 Recruiting - Aplastic Anemia Clinical Trials

A Study of Emapalumab for Pediatric Aplastic Anemia

Start date: May 21, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.

NCT ID: NCT06335277 Recruiting - Lymphoma Clinical Trials

Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology

Start date: February 22, 2018
Phase:
Study type: Observational

Patients eligible undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplant.

NCT ID: NCT06009965 Recruiting - Aplastic Anemia Clinical Trials

Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System

Start date: January 20, 2023
Phase: Phase 4
Study type: Interventional

In this study, investigators intend to prospectively study treatment-naive AA patients (including SAA and NSAA) who are non-transplant candidates in northern China. Patients with SAA receive ATG+CsA+Herombopag, and patients with NSAA receive CsA+ Herombopag. Investigators explored possible indicators of participants' predictive efficacy and built predictive models. After the participants achieved response, they used a tapering regimen, observed relapse and clonal evolution, and developed a predictive model of relapse.

NCT ID: NCT06004752 Recruiting - Aplastic Anemia Clinical Trials

Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly

Start date: August 17, 2023
Phase: Phase 2
Study type: Interventional

For elderly patients who cannot tolerate anti-thymocyte globulin (ATG) treatment, the addition of avatrombopag (AVA), which has a slight adverse reaction, can theoretically improve the hematological response rate in elderly patients with non-severe aplastic anemia (NSAA) without significantly increasing adverse reactions. Based on this, this study treated NSAA patients older than 60 with AVA combined with CsA to evaluate the hematological response rate and safety of AVA in the elderly who could not tolerate ATG therapy.

NCT ID: NCT05832216 Recruiting - Aplastic Anemia Clinical Trials

Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia

Start date: April 17, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1, prospective, single-arm, open-label study. The aim of this study is to evaluate the transfusion responses of platelet increment by using Daratumumab among aplastic anemia patients with platelet transfusion refractoriness.

NCT ID: NCT05571332 Recruiting - Aplastic Anemia Clinical Trials

Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy and safety of Avatrombopag combined with IST in very/sever aplastic anemia patients with abnormal liver function or HAAA patients treated for the first time. The design was: Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. Cyclosporine 3 mg/kg orally in two divided doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy, and Avatrombopag, which was administered in the dose of 40 mg orally once daily for a total of 12 weeks. Thirty-nine patients are expected to be enrolled in this study. Evaluation endpoint: complete response rate at 12 weeks of treatment.

NCT ID: NCT05510505 Recruiting - Aplastic Anemia Clinical Trials

GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

Start date: December 30, 2021
Phase: Phase 2
Study type: Interventional

Objectives 2.1 Primary objectives 1) To observe and compare incidence and severity of aGVHD and cGVHD between the two arms within 2 years after transplantation. 2) To observe and compare the engraftment rate between the two arms. 3) To observe and compare the incidence of infections between the two arms. 2.2 Secondary objectives 1. To conduct pharmacogenomic assay in CD20 arm(treatment arm) before conditioning and monitor plasma concentration of CD20 dynamically(7d、14d、28d、56d、91d). 2. To monitor levels of B cells in peripheral blood dynamically (+90d、+180d、+270d、+360d、+450d、+540d、+630d、+720d) in all patients. 3. To observe and compare the incidence of PTLD between the two arms. 4. To observe and compare immunoglobulin levels after transplantation in all patients. 5. To evaluate transplant-related mortality. 6. To evaluate the effect on hematopoietic reconstruction.

NCT ID: NCT05386264 Recruiting - Aplastic Anemia Clinical Trials

Autologous Tregs for Aplastic Anaemia

TIARA
Start date: July 14, 2022
Phase: Phase 1
Study type: Interventional

This Phase I study will determine the safety and optimal dose of expanded autologous Tregs to treat patients with Aplastic Anaemia (AA) (who have failed, or are considered ineligible for IST (immunosuppressive therapy) / other treatments) using expanded autologous T regulatory cells (Tregs) from AA patients at King's College Hospital, that have been prepared at the licensed Good Manufacturing Practices (GMP) production facility at Guy's Hospital, London

NCT ID: NCT05194397 Recruiting - Clinical trials for Myelodysplastic Syndromes

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

IAMFIT
Start date: March 21, 2023
Phase: Phase 2
Study type: Interventional

This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.

NCT ID: NCT05031897 Recruiting - Clinical trials for Acute Myeloid Leukemia

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

Start date: October 25, 2021
Phase: Phase 2
Study type: Interventional

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.